News

Captor Therapeutics wins prestigious EIC Accelerator recommendation for funding of project CT-03

Captor Therapeutics Announces Clinical Candidate for Project CT-03!

Captor Therapeutics has applied for approval to conduct a Phase 1 clinical trial in Patients with Hepatocellular Carcinoma

Captor Therapeutics has signed an agreement for the implementation and funding of Stage II of the CT-01 Project

Captor Therapeutics signed the agreement for II phase implementation and financing for Project CT-03

Captor Therapeutics has published financial report for Q1-Q3 2023.

Captor Therapeutics has submitted phasing applications to NCBiR for projects CT-01 and CT-03

Captor Therapeutics has selected ICON as the CRO company to conduct the first phase of clinical trials under the CT-01 project